NCT05947578View on ClinicalTrials.gov

The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 19, 2023

Primary Completion Date

August 9, 2024

Study Completion Date

August 9, 2024

Conditions
Charcot Marie Tooth Disease, Type 1
Interventions
DRUG

CLZ-2002

Low dose group (6×10\^6 cells), Mid dose group (12×10\^6 cells), High dose group (24×10\^6 cells)

Trial Locations (1)

06351

Samsung Medical center, Seoul

Sponsors
All Listed Sponsors
lead

Cellatoz Therapeutics, Inc

INDUSTRY

NCT05947578 - The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease. | Biotech Hunter | Biotech Hunter